| 20.6 -0.89 (-4.14%) | 10-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.72  |
1-year : | 29.1 |
| Resists | First : | 22.02 |
Second : | 24.92 |
| Pivot price | 22.23 |
|||
| Supports | First : | 17.32 |
Second : | 14.41 |
| MAs | MA(5) : | 21.79 |
MA(20) : | 22.2 |
| MA(100) : | 14.8  |
MA(250) : | 14.08 |
|
| MACD | MACD : | 0.9 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 19.6 |
D(3) : | 30.2 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 28.98 | Low : | 4.17 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SEPN ] has closed above bottom band by 1.9%. Bollinger Bands are 1.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.52 - 21.67 | 21.67 - 21.79 |
| Low: | 19.66 - 19.86 | 19.86 - 20.01 |
| Close: | 20.33 - 20.59 | 20.59 - 20.8 |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Fri, 31 Oct 2025
Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Mon, 27 Oct 2025
Septerna’s SEP-631 Study: A Potential Game-Changer in Pharmaceutical Research - TipRanks
Fri, 24 Oct 2025
Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Innovator with 11.29% Potential Upside - DirectorsTalk Interviews
Thu, 09 Oct 2025
Septerna (SEPN): Evaluating Valuation Following Dr. Keith Gottesdiener’s Board Appointment - Yahoo Finance
Thu, 09 Oct 2025
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance
Sun, 05 Oct 2025
We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 1.818e+007 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 3,170 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.006e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -24 % |
| Return on Assets (ttm) | 351.2 % |
| Return on Equity (ttm) | -21.6 % |
| Qtrly Rev. Growth | 726000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.57e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|